238 related articles for article (PubMed ID: 17624683)
1. Do polyunsaturated fatty acids behave like an endogenous "polypill"?
Das UN
Med Hypotheses; 2008; 70(2):430-4. PubMed ID: 17624683
[TBL] [Abstract][Full Text] [Related]
2. Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules.
Das UN
Lipids Health Dis; 2008 Oct; 7():37. PubMed ID: 18922179
[TBL] [Abstract][Full Text] [Related]
3. [The polypill: optimal strategy for reduction of cardiovascular disease].
Nathoe HM; Doevendans PA
Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1740. PubMed ID: 16114290
[TBL] [Abstract][Full Text] [Related]
4. Long-chain polyunsaturated fatty acids interact with nitric oxide, superoxide anion, and transforming growth factor-beta to prevent human essential hypertension.
Das UN
Eur J Clin Nutr; 2004 Feb; 58(2):195-203. PubMed ID: 14749737
[TBL] [Abstract][Full Text] [Related]
5. Folic acid and polyunsaturated fatty acids improve cognitive function and prevent depression, dementia, and Alzheimer's disease--but how and why?
Das UN
Prostaglandins Leukot Essent Fatty Acids; 2008 Jan; 78(1):11-9. PubMed ID: 18054217
[TBL] [Abstract][Full Text] [Related]
6. [The polypill: not an effective strategy for reduction of cardiovascular disease].
Westerweel PE; van Wijk JP; Verhaar MC
Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1741. PubMed ID: 16114291
[TBL] [Abstract][Full Text] [Related]
7. [The essential fatty acids omega-6 and omega-3: from their discovery to their use in therapy].
Caramia G
Minerva Pediatr; 2008 Apr; 60(2):219-33. PubMed ID: 18449139
[TBL] [Abstract][Full Text] [Related]
8. [The Polypill: between myths and reality in the treatment of type 2 diabetes mellitus].
Ruiz J; Egli M
Rev Med Suisse; 2006 May; 2(68):1480-2, 1484-5. PubMed ID: 16783994
[TBL] [Abstract][Full Text] [Related]
9. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases.
Simopoulos AP
Exp Biol Med (Maywood); 2008 Jun; 233(6):674-88. PubMed ID: 18408140
[TBL] [Abstract][Full Text] [Related]
10. [Potential value of omega-3 polyunsaturated fatty acids in the prevention of atherosclerosis and cardiovascular diseases].
d'Ivernois C; Couffinhal T; Le Métayer P; Haissaguerre M; Warin JF
Arch Mal Coeur Vaiss; 1992 Jun; 85(6):899-904. PubMed ID: 1417409
[TBL] [Abstract][Full Text] [Related]
11. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
Carey KM; Comee MR; Donovan JL; Kanaan AO
Ann Pharmacother; 2012 May; 46(5):688-95. PubMed ID: 22570437
[TBL] [Abstract][Full Text] [Related]
12. [The role of omega-3 fatty acids from fish in prevention of cardiovascular diseases].
Reiner E; Tedeschi-Reiner E; Stajminger G
Lijec Vjesn; 2007; 129(10-11):350-5. PubMed ID: 18257336
[TBL] [Abstract][Full Text] [Related]
13. The Polypill in the prevention of cardiovascular disease.
Wald DS; Wald NJ
Prev Med; 2011 Jan; 52(1):16-7. PubMed ID: 21130112
[No Abstract] [Full Text] [Related]
14. Benefits, challenges, and registerability of the polypill.
Sleight P; Pouleur H; Zannad F
Eur Heart J; 2006 Jul; 27(14):1651-6. PubMed ID: 16603580
[TBL] [Abstract][Full Text] [Related]
15. The future of metabolic syndrome and cardiovascular disease prevention: polyhype or polyhope? Tales from the polyera.
Franco OH; Karnik K; Bonneux L
Horm Metab Res; 2007 Sep; 39(9):627-31. PubMed ID: 17846968
[TBL] [Abstract][Full Text] [Related]
16. [Prevention of cardiovascular diseases using a combined pharmacological approach: is there any place for a "polypill"?].
Scheen AJ; Lefèbvre PJ; Kulbertus H
Rev Med Liege; 2003 Sep; 58(9):527-33. PubMed ID: 14626644
[TBL] [Abstract][Full Text] [Related]
17. Essential fatty acids.
Lerman RH
Altern Ther Health Med; 2006; 12(3):20-9; quiz 30-1. PubMed ID: 16708767
[No Abstract] [Full Text] [Related]
18. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
[TBL] [Abstract][Full Text] [Related]
19. Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids.
Robinson JG; Stone NJ
Am J Cardiol; 2006 Aug; 98(4A):39i-49i. PubMed ID: 16919516
[TBL] [Abstract][Full Text] [Related]
20. The omega-6/omega-3 fatty acid ratio, genetic variation, and cardiovascular disease.
Simopoulos AP
Asia Pac J Clin Nutr; 2008; 17 Suppl 1():131-4. PubMed ID: 18296320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
